健康受试者单次和多次口服替戈拉生与瑞伐拉生的药效学研究
在幽门螺杆菌阴性的健康韩国男性受试者中开展随机、开放标签、阳性对照研究,比较替戈拉生50 mg与瑞伐拉生200 mg每日一次口服7天后的24小时胃内pH监测和血清胃泌素。结果显示替戈拉生对胃酸的抑制作用强于瑞伐拉生,两者耐受性均良好。
要点
- 单次给药后替戈拉生%Time pH≥4为54.5%,高于瑞伐拉生的25.1%。
- 多次给药后替戈拉生%Time pH≥4为68.2%,高于瑞伐拉生的25.3%。
- 夜间12小时%Time pH≥4替戈拉生为71.8%,高于瑞伐拉生的31.9%。
核心结论
- 替戈拉生50 mg对胃酸的抑制作用强于瑞伐拉生200 mg,两者耐受性均良好。
研究设计与样本
- 随机、开放标签、阳性对照研究,纳入幽门螺杆菌阴性的健康韩国男性受试者。
- 替戈拉生50 mg或瑞伐拉生200 mg口服,每日一次,连续7天。
- 通过24小时胃内pH监测和血清胃泌素进行药效学评价,并收集包括血清microRNA-122(miR-122)在内的安全性参数。
主要发现
- 单次给药后,替戈拉生%Time pH≥4为54.5%,瑞伐拉生为25.1%,替戈拉生更高。
- 多次给药后,替戈拉生%Time pH≥4为68.2%,瑞伐拉生为25.3%,替戈拉生更高。
- 夜间12小时%Time pH≥4,替戈拉生为71.8%,瑞伐拉生为31.9%,替戈拉生更高。
- 两种药物的血清胃泌素变化均无临床意义。
- 尽管每种药物的血清miR-122均轻度升高,但结合包括AST和ALT水平在内的其他安全性参数,替戈拉生和瑞伐拉生均耐受性良好。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Potassium-competitive acid blockers (P-CABs) are emerging as novel treatments for acid-related disorders including gastroesophageal reflux disease. Tegoprazan and revaprazan are approved P-CABs in South Korea, but the pharmacodynamics and safety/tolerability of the two drugs have never been compared. AIMS: To evaluate the pharmacodynamics and safety/tolerability of tegoprazan and revaprazan after single and multiple oral doses METHODS: A randomised, open-label, active-controlled study was conducted in Helicobacter pylori-negative healthy Korean male subjects. Tegoprazan 50 mg or revaprazan 200 mg was administered orally, once daily for 7 days; 24-h intragastric pH monitoring and serum gastrin were measured for pharmacodynamic evaluation. Safety parameters including serum microRNA-122 (miR-122) level were also collected. RESULTS: After a single dose, the %Time pH ≥4 for tegoprazan was greater than that for revaprazan (54.5% vs 25.1%). After multiple doses, the %Time pH ≥4 for tegoprazan was also greater than that for revaprazan (68.2% vs 25.3%). %Time pH ≥4 during 12 hours at nighttime for tegoprazan was greater than that for revaprazan (71.8% vs 31.9%). The changes in the serum gastrin were not clinically significant for either drug. Despite the slight increases of serum miR-122 for each drug, tegoprazan and revaprazan were well tolerated considering other safety parameters including AST and ALT levels. CONCLUSION: Tegoprazan 50 mg showed stronger gastric acid suppression than revaorazan 200 mg. Both drugs were well tolerated.
引用
- Sunwoo J, Ji SC, Oh J, et al. Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects. Aliment Pharmacol Ther. 2020. PMID: 33131095. doi:10.1111/apt.16121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。